Buzzing Politics
  • News
  • Privacy Policy
  • Terms of Use
  • Disclaimer
Select Page
Casey’s Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Casey’s Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

by Avi Kapoor | Mar 9, 2026 | General

Casey’s General Stores, Inc. (NASDAQ:CASY) will release earnings results for its third quarter, after the closing bell on Monday, March 9. Analysts expect the Ankeny, Iowa-based company to report quarterly earnings at $2.97 per share, up from $2.33 per share in the...

Trump Promised Half-Price Energy. His Iran War Delivered $119 Oil Instead

by Surbhi Jain | Mar 9, 2026 | General

Cheap energy was supposed to be the easy win for the Trump administration. Instead, oil markets are moving in the opposite direction. Crude briefly surged to around $119 per barrel, the highest level since 2022, as escalating tensions involving the U.S., Israel and...

This Valaris Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

by Avi Kapoor | Mar 9, 2026 | General

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BTIG analyst Gregory Lewis downgraded the rating for Valaris Ltd...

Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures

by Vandana Singh | Mar 9, 2026 | General

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) shares are up during Monday’s premarket session following the announcement of positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures. Positive topline results were reported from the...

Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism

by Vandana Singh | Mar 9, 2026 | General

Dianthus Therapeutics Inc. (NASDAQ:DNTH) shares are up during Monday’s premarket session following an early GO decision announced by the company based on an interim responder analysis in the Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating...
« Older Entries
Next Entries »

Recent Posts

  • Micron, Carvana, Cloudflare, Comcast And Barrick Mining: Why These 5 Stocks Are On Investors’ Radars Today
  • Trump Allegedly Told Larry Ellison ‘I’ll Make Sure You Get’ Warner Bros, New Lawsuit Claims
  • Tesla Just Snubbed TSMC — Musk Is Quietly Building A Sovereign Chip Chain
  • Swarmer Stock Cools Off After The Close Wednesday: What To Know
  • DLocal Stock Turns Green After Q4 Earnings: Here’s Why

Recent Comments

    Archives

    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019

    Categories

    • Breaking
    • Business
    • Daily
    • General
    • Markets
    • News
    • Reports
    • Technology

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • News
    • Privacy Policy
    • Terms of Use
    • Disclaimer
    Copyright 2019 Karmaholic Media LLC. All Rights Reserved.